Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Circulation

• Publication date

  2003-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000068340.96506.0FPMID 12732605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.

  2001cited by this paper
• Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction.

  2001cited by this paper
• Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.

  2001cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)

  2000cited by this paper
• Steroidogenic enzyme gene expression in the human heart.

  2000cited by this paper
• Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.

  2000cited by this paper
• Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction.

  2000cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart.

  1995cited by this paper
• The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction.

  1995cited by this paper
• Chronic mineralocorticoid excess and cardiovascular remodeling.

  1995cited by this paper
• Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone.

  1994cited by this paper
• Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.

  1994cited by this paper
• Activation of neurohumoral systems in postinfarction left ventricular dysfunction.

  1993cited by this paper
• Thrombolytic Therapy With Streptokinase Stimulates Collagen Breakdown

  1991cited by this paper
• Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.

  1991cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications

  1990cited by this paper
• Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two-dimensional echocardiography.

  1989cited by this paper

• Risk of Delaying or Omitting Mineralocorticoid Receptor Antagonists in Heart Failure

  2026cites this paper
• Serum aminoterminal type III procollagen peptide reflects increased vascular thickness in healthy, young adults

  2026cites this paper
• Global Research Trends in Oxidative Stress and Myocardial Fibrosis: A Dual-Software Bibliometric Study

  2025cites this paper
• Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review.

  2025cites this paper
• Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.

  2025cites this paper
• Mineralocorticoid receptor antagonists for acute myocardial infarction: a systematic review and meta-analysis of randomised controlled trials

  2025cites this paper
• Cardiovascular effects of mineralocorticoid receptor antagonists in acute coronary syndrome: an updated systematic review and meta-analysis of randomized clinical trials.

  2025cites this paper
• Machine-learning based calculator for personalized risk assessment following ST-elevation myocardial infarction

  2025cites this paper
• Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice

  2025cites this paper
• Life-saving Drug or Potential Threat? The Role of Mineralocorticoid Receptor Antagonists in Myocardial Infarction: A Meta-Analysis.

  2025cites this paper
• Up-to-date advance in the relationship between obstructive sleep apnea and heart failure: a narrative review

  2024cites this paper
• Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta‐analysis

  2024cites this paper
• Overview of research progress on the association of dietary potassium intake with serum potassium and survival in hemodialysis patients, does dietary potassium restriction really benefit hemodialysis patients?

  2023cites this paper
• Role of aldosterone in mid‐ and long‐term left ventricular remodelling after acute myocardial infarction: The REMI study

  2023cites this paper
• Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

  2023cites this paper
• Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients

  2023cites this paper
• Toward Parsing the Heterogeneity in Post-MI LV Remodeling.

  2023cites this paper
• REMIniscence of aldosterone's role in myocardial remodelling

  2023cites this paper
• An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook

  2022cites this paper
• The impact of medical therapy on left ventricular strain: Current state and future perspectives

  2022cites this paper
• Atrial fibrillation in heart failure patients: An update on renin–angiotensin–aldosterone system pathway blockade as a therapeutic and prevention target

  2022influential citation
• Galunisertib-Loaded Gelatin Methacryloyl Hydrogel Microneedle Patch for Cardiac Repair after Myocardial Infarction

  2022cites this paper
• Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction

  2022cites this paper
• Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood

  2022cites this paper
• Reverse re-modelling chronic heart failure by reinstating heart rate variability

  2022cites this paper
• Aldosterone as a Mediator of Cardiovascular Damage.

  2022cites this paper
• Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling.

  2022cites this paper
• Heart Failure with Improved Ejection Fraction: Insight into the Variable Nature of Left Ventricular Systolic Function

  2022cites this paper
• Role of Puerarin in Pathological Cardiac Remodeling: A Review.

  2022cites this paper
• Association of Aldosterone with Mortality in the General Population

  2022cites this paper
• Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

  2022cites this paper
• Antialdosterone in Acute Myocardial Infarction patients: a Meta-Analysis and Systematic Review

  2021cites this paper
• Effects of paeonol on proliferation and collagen synthesis of rat cardiac fibroblasts induced by aldosterone

  2021cites this paper
• Fibroblast‐mediated intercellular crosstalk in the healthy and diseased heart

  2021cites this paper
• Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients With Left Ventricular Dysfunction Post‐ST‐Segment–Elevation Myocardial Infarction

  2021cites this paper
• Epicardial Adiposity in Relation to Metabolic Abnormality, Circulating Adipocyte FABP, and Preserved Ejection Fraction Heart Failure

  2021cites this paper
• Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials

  2021cites this paper
• Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction

  2021cites this paper
• RAAS: A Convergent Player in Ischemic Heart Failure and Cancer

  2021cites this paper
• Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction

  2020cites this paper
• RAS inhibition in resident fibroblast biology.

  2020cites this paper
• Health-Related Quality of Life in the Spironolactone to Reduce ICD Therapy (SPIRIT) Trial

  2020cites this paper
• THE ROLE OF ALDOSTERONE INHIBITORS ON CARDIAC ISCHEMIA/REPERFUSION INJURY.

  2020cites this paper
• Left ventricular remodelling after ST‐segment elevation myocardial infarction: sex differences and prognosis

  2020cites this paper
• Diverse origins and activation of fibroblasts in cardiac fibrosis.

  2020cites this paper
• Mineralocorticoid Receptor Antagonists in the Treatment of Coronary Artery Disease, Myocardial Infarction and Heart Failure

  2019cites this paper
• Effects of Doxycycline on Left Ventricular Remodeling in Patients With Acute Anterior Myocardial Infarction Uundergoing Primary Angioplasty: A Randomized Clinical Trial

  2019cites this paper
• Unveiling the CCBE1 role on human iPSC-derived cardiac fibroblasts differentiation and functionality

  2019cites this paper
• Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis

  2019cites this paper
• Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without

  2019cites this paper
• Dynamics of biochemical markers of systemic inflammatory response and renal functional condition in patients with myocardial infarction without ST-elevation in the dependence of the use of the blоcker of mineralocortycoіde receptors of eplerenone for the 3 and 6 months

  2019cites this paper
• Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.

  2019cites this paper
• The Role of Hyperaldosteronism in the Pathogenesis of Neuroleptic Cardiomyopathy

  2019cites this paper
• Fibroblasts in the Infarcted, Remodeling, and Failing Heart

  2019cites this paper
• Unresolved issues in left ventricular postischemic remodeling and progression to heart failure.

  2019cites this paper
• The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure

  2019cites this paper
• Cardiac Remodeling: The Course Towards Heart Failure-II. Diagnostic and Therapeutic Approaches

  2019cites this paper
• The role of aldosterone and mineralocorticoid receptor antagonists in cardiovascular damage

  2019cites this paper
• Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis

  2019cites this paper
• Role of spironolactone in the treatment of heart failure with preserved ejection fraction.

  2018cites this paper
• Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction

  2018cites this paper
• Echocardiographic diastolic function evolution in patients with an anterior Q‐wave myocardial infarction: insights from the REVE‐2 study

  2018cites this paper
• eplerenone on the dynamics of the structural-functional state of the myocardium in patients with non Q-wave myocardial infarction after 3 and 6 months of treatment

  2018cites this paper
• Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction

  2018cites this paper
• Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

  2018cites this paper
• Heart failure complicating myocardial infarction. A report of the Peruvian Registry of ST-elevation myocardial infarction (PERSTEMI).

  2018cites this paper
• The role of mineralocorticoid receptor antagonists in patients with acute myocardial infarction: Is the evidence reflective of modern clinical practice?

  2018cites this paper
• Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis

  2018cites this paper
• Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial

  2018cites this paper
• Dynamics of biochemical markers of systemic inflammatory response and renal functional condition in patients with myocardial infarction without ST elevation in the dependence of percutaneous angioplasty

  2018cites this paper
• Structural Remodeling in the Development of Chronic Systolic Heart Failure: Implication for Treatment

  2017cites this paper
• Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study

  2017cites this paper
• Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association.

  2017cites this paper
• Mechanisms of Fibroblast Activation in the Remodeling Myocardium

  2017cites this paper
• A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention.

  2017cites this paper
• Kardiales Remodelling nach Myokardinfarkt

  2017cites this paper
• Left ventricular eccentricity index measured with SPECT myocardial perfusion imaging: An additional parameter of adverse cardiac remodeling

  2017cites this paper
• Kardiales Remodelling nach Myokardinfarkt

  2017cites this paper
• Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

  2017cites this paper
• [Cardiac remodeling after myocardial infarction : Clinical practice update].

  2017cites this paper
• Mineralocorticoid receptor antagonists in patients with acute myocardial infarction — A systematic review and meta‐analysis of randomized trials

  2017cites this paper
• Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure

  2017cites this paper
• Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target.

  2017cites this paper
• Allele status of aldosterone synthase (CYP11B2) gene polymorphism and cardiac remodeling after ST segment elevation myocardial infarction

  2017influential citation
• No Evidence for Femoral Pulse Evaluation in Normotensive College Athletes During Sports Preparticipation Examinations.

  2016cites this paper
• MRAs in Patients With AMI Without Early Evidence of Heart Failure: Time for Reappraisal?

  2016cites this paper
• Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure

  2016cites this paper
• Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.

  2016cites this paper
• Latest aspects of aldosterone actions on the heart muscle.

  2016cites this paper
• Genomic and rapid effects of aldosterone: what we know and do not know thus far

  2016cites this paper
• Ventricular fibrogenesis activity assessed by serum levels of procollagen type III N-terminal amino peptide during the staged Fontan procedure.

  2016cites this paper
• Reply: Mineralocorticoid Receptor Antagonism in Acute Myocardial Infarction: Who Benefits?

  2016cites this paper
• IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial

  2016cites this paper
• Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases

  2015cites this paper
• Protective effects of spironolactone against anthracycline‐induced cardiomyopathy

  2015cites this paper
• The N-Terminal Propeptide of Type III Procollagen in Patients with Acute Coronary Syndrome: A Link between Left Ventricular End-Diastolic Pressure and Cardiovascular Events

  2015cites this paper
• Current and Future Strategies for the Diagnosis and Treatment of Cardiac Fibrosis

  2015cites this paper
• Eplerenone in chronic heart failure with depressed systolic function.

  2015cites this paper
• CARDIAC BIOMARKERS: PAST, PRESENT AND FUTURE

  2015cites this paper
• Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design

  2015cites this paper